1 / 7

Survival Differences Among AML Patients Treated with HCT Versus Non-HCT Therapies: Prospective Observational Study

This study compares the survival outcomes of AML patients treated with allogeneic hematopoietic cell transplantation (HCT) versus non-HCT therapies. Results suggest a survival advantage with HCT, especially in patients with unfavorable ELN risk and vulnerable patients. However, adjusting for AML-specific and patient-specific variables negated the observed benefit.

delder
Download Presentation

Survival Differences Among AML Patients Treated with HCT Versus Non-HCT Therapies: Prospective Observational Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018

  2. Introduction • Population-based studies also indicate overall improvement in survival of older (60-80 years old) AML patients (Bower, Blood Cancer Journal, 2016) • Only a small minority (6%-8%) of them receive HCT (Medeiros, Ann Hematol. 2015). • Prospective multi-center longitudinal study • First presentation of adults with AML to treatment • Compared survival according to whether or not pts received HCT at later time points

  3. Results • Median follow-up = 16.8 months (range, 0.1–52.4) • 2-years survival rate after HCT: 58% • In the unadjusted model, a survival advantage was associated with receiving allogeneic HCT compared with no transplantation, P = 0.0003 • The survival advantage for allogeneic HCT was observed in patients with intermediate (P = 0.0005) or unfavorable (P < 0.0001) ELN risk and in vulnerable patients (P < 0.0001)  • In the adjusted model for AML- and patient-specific variables, there was no survival benefit observed for allogeneic HCT, P = 0.21

  4. Conclusion • Adjusting for key AML-specific and pt-specific variables negated the observed benefit of HCT over non-HCT therapies in reducing mortality rates among AML pts. Results might reflect 1) improvement in supportive care and non-HCT therapies 2) a relatively high non-relapse mortality early after HCT and the need for longer follow-up to demonstrate an adjusted benefit of HCT 3) the high selectivity of the transplant eligibility process, as we accounted here for variables that are often ignored in “genetic assignment” randomized studies (i.e. comorbidities and function). • New randomized trials are needed

More Related